How much does ixazomib cost in Medicare? Reimbursement ratio

Ixazomib: is an oral proteasome inhibitor widely used to treat multiple myeloma. Its price is relatively high, which can become a burden for most patients. The common dosage forms of ixazomib are capsules, with common strengths of 4 mg, 3 mg and 2.5 mg. Each box contains 3 plates. Depending on the specifications of the drug and the region, the market price of ixazomib usually ranges from more than 10,000 yuan. Although the price is higher, ixazomib has been approved in China and has been included in the Class B medical insurance directory, which allows patients to reduce their financial burden to a certain extent through medical insurance reimbursement.

In terms of medical insurance reimbursement, ixazomib is included in the Class B medical insurance drugs, which means that most patients can reimburse part of their expenses through medical insurance if they meet the conditions for medical insurance. However, the specific reimbursement rate depends on the patient's region and type of health insurance, as well as the dosage of the drug. Under normal circumstances, the reimbursement ratio of medical insurance may be between 60% and 80%, and the patient's out-of-pocket expenses will be greatly reduced, but it still needs to be confirmed according to the specific policies of the region. In some cases, patients may be required to pay a portion of their out-of-pocket drug costs, especially if insurance reimbursement is insufficient.

For patients, the coverage and proportion of medical insurance reimbursement may vary from region to region, so it is recommended that patients confirm the specific cost burden with the hospital's pharmacy or medical insurance department before starting treatment. At the same time, some regions or hospitals may provide drug assistance programs to help patients with financial difficulties reduce treatment costs. These assistance programs can further alleviate financial pressure on patients and ensure they can continue to receive necessary treatment.

Generally speaking, although the price of ixazomib is relatively high, after being included in medical insurance, patients can reduce the burden of treatment through medical insurance. The specific reimbursement ratio needs to be determined according to regional and medical insurance policies.

Reference materials:https://www.ninlaro.com/